Skip to Content

1,187 Results Found

  • Article
  • Open Access
1 Citations
533 Views
22 Pages

BIX02189 Suppresses Adipogenesis and Lipid Accumulation Through Inhibition of MEK5-STAT3/STAT5 Signaling and Activation of AMPK in Adipocytes and Zebrafish

  • Nivethasri Lakshmana Perumal,
  • Muneer Hussain,
  • Dae-Gu Son,
  • Jacqueline M. Stephens and ,
  • Gi-Young Park and
  • Byeong-Churl Jang
  • + 1 author+ 0 author

Obesity is a major metabolic disorder characterized by excessive lipid accumulation and adipocyte differentiation. The mitogen-activated protein kinase kinase 5 (MEK5) signaling pathway has been implicated in diverse cellular processes; however, its...

(This article belongs to the Special Issue Obesity: From Cellular Mechanism to Potential Molecular Therapies)
  • Article
  • Open Access
4 Citations
3,451 Views
17 Pages

Mechanism of Abnormal Activation of MEK1 Induced by Dehydroalanine Modification

  • Yue Zhao,
  • Shan-Shan Du,
  • Chao-Yue Zhao,
  • Tian-Long Li and ,
  • Si-Cheng Tong and
  • Li Zhao
  • + 1 author+ 0 author

Mitogen-activated protein kinase kinase 1 (MAPK kinase 1, MEK1) is a key kinase in the mitogen-activated protein kinase (MAPK) signaling pathway. MEK1 mutations have been reported to lead to abnormal activation that is closely related to the malignan...

(This article belongs to the Section Molecular Biophysics)
  • Review
  • Open Access
77 Citations
12,688 Views
21 Pages

The MEK5/ERK5 Pathway in Health and Disease

  • Rupesh Paudel,
  • Lorenza Fusi and
  • Marc Schmidt

The MEK5/ERK5 mitogen-activated protein kinases (MAPK) cascade is a unique signaling module activated by both mitogens and stress stimuli, including cytokines, fluid shear stress, high osmolarity, and oxidative stress. Physiologically, it is mainly k...

(This article belongs to the Special Issue Signal Transduction: From Molecular Pathways to Translational Research)
  • Article
  • Open Access
4 Citations
1,196 Views
15 Pages

28 February 2026

Plexiform neurofibromas associated with neurofibromatosis type I (pNF1s) are benign tumors caused by the complete loss of function of the NF1 gene, which encodes a negative regulator of the RAS/mitogen-activated protein kinase (MAPK) pathway. pNF1s c...

(This article belongs to the Section Cell Microenvironment)
  • Article
  • Open Access
9 Citations
5,505 Views
18 Pages

5 November 2022

BRAF V600E mutation drives uncontrolled cell growth in most melanomas. While BRAF V600E tumors are initially responsive to BRAF inhibitors, prolonged treatment results in inhibitor resistance and tumor regrowth. Clinical data have linked the NRAS Q61...

(This article belongs to the Special Issue Targeting the (Un)Usual Suspects in Cancer)
  • Review
  • Open Access
726 Views
22 Pages

Toll-like receptors (TLRs) are essential components of the innate immune system that enable host cells to sense microbial and endogenous danger signals and to initiate inflammatory and antimicrobial responses. Activation of TLRs triggers complex intr...

(This article belongs to the Special Issue The Role of Toll-Like Receptors (TLRs) in Infection and Inflammation: 4th Edition)
  • Article
  • Open Access
14 Citations
2,782 Views
13 Pages

Tegaserod Maleate Suppresses the Growth of Gastric Cancer In Vivo and In Vitro by Targeting MEK1/2

  • Zitong Wang,
  • Yingying Chen,
  • Xiaoyu Li,
  • Yuhan Zhang and ,
  • Xiaokun Zhao,
  • Hao Zhou,
  • Xuebo Lu,
  • Lili Zhao,
  • Qiang Yuan and
  • Kangdong Liu
  • + 9 authors+ 4 authors

23 July 2022

Gastric cancer (GC) ranks fifth in global incidence and fourth in mortality. The current treatments for GC include surgery, chemotherapy and radiotherapy. Although treatment strategies for GC have been improved over the last decade, the overall five-...

  • Review
  • Open Access
8 Citations
4,598 Views
19 Pages

MEK Inhibition in Glioblastoma: Current Perspectives and Future Directions

  • Adam Shapira Levy,
  • Jean-Paul Bryant,
  • David Matichak,
  • Shumpei Onishi and
  • Yeshavanth Kumar Banasavadi-Siddegowda

The Mitogen-activated protein kinase kinase (MEK) protein family has dual-specificity protein kinases with a myriad of cellular functions that include but are not limited to cell survival, cell division, immunologic response, angiogenesis, and cellul...

(This article belongs to the Special Issue Novel Therapeutic Targets in Cancers: 3rd Edition)
  • Review
  • Open Access
240 Citations
16,949 Views
20 Pages

26 September 2017

The current development status of mitogen-activated protein kinase kinase (MEK) inhibitors, including the preclinical data and clinical study progress, has been summarized in this review. Different MEK inhibitors, possessing specific physicochemical...

(This article belongs to the Special Issue Kinase Inhibitors)
  • Review
  • Open Access
19 Citations
6,403 Views
17 Pages

2 October 2023

BRAF is one of the most frequently mutated oncogenes, with an overall frequency of about 50%. Targeting BRAF and its effector mitogen-activated protein kinase kinase 1/2 (MEK1/2) is now a key therapeutic strategy for BRAF-mutant tumors, and therapies...

(This article belongs to the Special Issue MAPK Signaling Cascades in Human Health and Diseases)
  • Article
  • Open Access
16 Citations
5,322 Views
15 Pages

Computational Study on the Effect of Inactivating/Activating Mutations on the Inhibition of MEK1 by Trametinib

  • Jingxuan Zhu,
  • Congcong Li,
  • Hengzheng Yang,
  • Xiaoqing Guo and ,
  • Tianci Huang and
  • Weiwei Han
  • + 1 author+ 0 author

Activation of the mitogen-activated protein kinase (MAPK) signaling pathway regulated by human MAP kinase 1 (MEK1) is associated with the carcinogenesis and progression of numerous cancers. In addition, two active mutations (P124S and E203K) have bee...

(This article belongs to the Special Issue Molecular Dynamics Simulations 2.0)
  • Article
  • Open Access
5 Citations
3,607 Views
12 Pages

Allosteric and ATP-Competitive MEK-Inhibition in a Novel Spitzoid Melanoma Model with a RAF- and Phosphorylation-Independent Mutation

  • Luca Hegedüs,
  • Özlem Okumus,
  • Elisabeth Livingstone,
  • Marcell Baranyi and ,
  • Ildikó Kovács,
  • Balázs Döme,
  • József Tóvári,
  • Ágnes Bánkfalvi,
  • Dirk Schadendorf and
  • Balázs Hegedüs
  • + 6 authors+ 1 author

16 February 2021

Spitzoid melanoma is a rare malignancy with histological characteristics similar to Spitz nevus. It has a diverse genetic background and in adults, a similarly grim clinical outcome as conventional malignant melanoma. We established a spitzoid melano...

(This article belongs to the Special Issue Therapeutic Strategies for Metastatic Melanomas)
  • Article
  • Open Access
4 Citations
3,591 Views
10 Pages

4 May 2021

To investigate whether the beiging process changes the interactive effects of salt and MEK6 gene on inflammatory adipogenesis, the salt treatment (NaCl 50 mM) and MEK6 transfection of Tg(+/+) cells were performed with white adipocytes (WAT) and beige...

(This article belongs to the Collection Research on Adipose Stem Cells)
  • Review
  • Open Access
22 Citations
5,406 Views
23 Pages

Pathophysiological Impact of the MEK5/ERK5 Pathway in Oxidative Stress

  • Ignazia Tusa,
  • Alessio Menconi,
  • Alessandro Tubita and
  • Elisabetta Rovida

13 April 2023

Oxidative stress regulates many physiological and pathological processes. Indeed, a low increase in the basal level of reactive oxygen species (ROS) is essential for various cellular functions, including signal transduction, gene expression, cell sur...

(This article belongs to the Section Cell Signaling)
  • Article
  • Open Access
25 Citations
5,985 Views
20 Pages

The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian Carcinoma

  • Mikhail S. Chesnokov,
  • Imran Khan,
  • Yeonjung Park,
  • Jessica Ezell and ,
  • Geeta Mehta,
  • Abdelrahman Yousif,
  • Linda J. Hong,
  • Ronald J. Buckanovich,
  • Akimasa Takahashi and
  • Ilana Chefetz
  • + 5 authors+ 0 author

18 March 2021

High-grade serous ovarian carcinoma (HGSOC) is the deadliest of gynecological cancers due to its high recurrence rate and acquired chemoresistance. RAS/MEK/ERK pathway activation is linked to cell proliferation and therapeutic resistance, but the rol...

(This article belongs to the Special Issue Cancer Stem Cells and Therapy Resistance)
  • Article
  • Open Access
7 Citations
4,385 Views
18 Pages

A Predictive Model of Adaptive Resistance to BRAF/MEK Inhibitors in Melanoma

  • Emmanuelle M. Ruiz,
  • Solomon A. Alhassan,
  • Youssef Errami,
  • Zakaria Y. Abd Elmageed and ,
  • Jennifer S. Fang,
  • Guangdi Wang,
  • Margaret A. Brooks,
  • Joe A. Abi-Rached,
  • Emad Kandil and
  • Mourad Zerfaoui
  • + 5 authors+ 0 author

The adaptive acquisition of resistance to BRAF and MEK inhibitor-based therapy is a common feature of melanoma cells and contributes to poor patient treatment outcomes. Leveraging insights from a proteomic study and publicly available transcriptomic...

(This article belongs to the Special Issue Immunomodulation of Skin Cancer)
  • Article
  • Open Access
9 Citations
3,990 Views
18 Pages

17 December 2021

Obesity is a state of abnormal fat accumulation caused by an energy imbalance potentially caused by changes in multiple factors. MEK6 engages in cell growth, such as inflammation and apoptosis, as one of the MAPK signaling pathways. The MEK6 gene was...

(This article belongs to the Section Biochemistry)
  • Article
  • Open Access
8 Citations
3,425 Views
19 Pages

MEK Is a Potential Indirect Target in Subtypes of Head and Neck Cancers

  • Bianka Gurbi,
  • Diána Brauswetter,
  • Kinga Pénzes,
  • Attila Varga and ,
  • Tibor Krenács,
  • Kornél Dános,
  • Ede Birtalan,
  • László Tamás and
  • Miklós Csala
  • + 4 authors+ 0 author

1 February 2023

The poor prognosis of head-and-neck squamous cell carcinoma (HNSCC) is partly due to the lack of reliable prognostic and predictive markers. The Ras/Raf/MEK/ERK signaling pathway is often activated by overexpressed epidermal growth factor receptor (E...

(This article belongs to the Special Issue Biomarkers of Tumor Progression, Prognosis and Therapy)
  • Review
  • Open Access
17 Citations
6,221 Views
25 Pages

RAF and MEK Inhibitors in Non-Small Cell Lung Cancer

  • Christos Adamopoulos,
  • Kostas A. Papavassiliou,
  • Poulikos I. Poulikakos and
  • Athanasios G. Papavassiliou

Lung cancer, despite recent advancements in survival rates, represents a significant global health burden. Non-small cell lung cancer (NSCLC), the most prevalent type, is driven largely by activating mutations in Kirsten rat sarcoma viral oncogene ho...

(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
  • Article
  • Open Access
1 Citations
489 Views
17 Pages

Structural and Biophysical Analyses of Human MEK2 in Complex with Two Inhibitors Reveal the Determinants of Isoform-Dependent Inhibitor Binding

  • Sang Won Cheon,
  • Eunmi Hwang,
  • Gi Baek Lee,
  • Yoonyoung Heo and ,
  • Hyoun Sook Kim and
  • Byung Woo Han
  • + 1 author+ 0 author

Selective inhibition of MEK isoforms remains a central challenge in MAPK-targeted drug discovery, largely due to the structural similarity between MEK1 and MEK2. While MEK1 has been extensively characterized, the structural basis of MEK2-specific lig...

(This article belongs to the Section Molecular Biology)
  • Communication
  • Open Access
4 Citations
3,241 Views
9 Pages

Imaging the Raf–MEK–ERK Signaling Cascade in Living Cells

  • Young-Chul Shin,
  • Minkyung Cho,
  • Jung Me Hwang,
  • Kyungjae Myung and ,
  • Hee-Seok Kweon,
  • Zee-Won Lee,
  • Hyun-A. Seong and
  • Kyung-Bok Lee
  • + 3 authors+ 0 author

1 October 2024

Conventional biochemical methods for studying cellular signaling cascades have relied on destructive cell disruption. In contrast, the live cell imaging of fluorescent-tagged transfected proteins offers a non-invasive approach to understanding signal...

(This article belongs to the Section Biochemistry)
  • Article
  • Open Access
18 Citations
4,753 Views
12 Pages

12 November 2019

Amplification and overexpression of the myeloid cell leukemia differentiation protein MCL1 and the murine double minute protein MDM2 have been reported in various human tumors as well as hematological malignancies including acute myeloid leukemia (AM...

(This article belongs to the Special Issue Acute Myeloid Leukemia)
  • Review
  • Open Access
102 Citations
15,677 Views
13 Pages

23 September 2015

Colorectal cancer (CRC) is a heterogeneous disease with multiple underlying causative genetic mutations. Genetic mutations in the phosphatidylinositol-3 kinase (PI3K) and the mitogen activated protein kinase (MAPK) pathways are frequently implicated...

(This article belongs to the Special Issue Molecular Classification of Human Cancer: Diagnosis and Treatment)
  • Article
  • Open Access
5 Citations
3,287 Views
12 Pages

Assessment of Retinal Pigment Epithelium Alterations and Chorioretinal Vascular Network Analyses in Patients under Treatment with BRAF/MEK Inhibitor for Different Malignancies: A Pilot Study

  • Giuseppe Fasolino,
  • Gil Awada,
  • Laura Moschetta,
  • Jorgos Socrates Koulalis and ,
  • Bart Neyns,
  • Bert Verhelst,
  • Peter Van Elderen,
  • Pieter Nelis,
  • Paul Cardon de Lichtbuer and
  • Marcellinus Ten Tusscher
  • + 6 authors+ 1 author

3 February 2023

In the last two decades, an increasing number of so-called molecular-targeted therapies have become available for the treatment of patients with advanced malignancies. These drugs have included inhibitors of proteins in the MAPK pathway, such as BRAF...

(This article belongs to the Section Ophthalmology)
  • Article
  • Open Access
2 Citations
2,779 Views
14 Pages

11 November 2021

Compared to other ethnicities, Hispanic children incur the highest rates of leukemia, and most cases are diagnosed as Acute Lymphoblastic Leukemia (ALL). Despite improved treatment and survival for ALL, disproportionate health outcomes in Hispanics p...

(This article belongs to the Section Molecular Oncology)
  • Article
  • Open Access
14 Citations
3,407 Views
25 Pages

23 February 2023

The second leading cause of death in the world is cancer. Mitogen-activated protein kinase (MAPK) and extracellular signal-regulated protein kinase (ERK) 1 and 2 (MEK1/2) stand out among the different anticancer therapeutic targets. Many MEK1/2 inhib...

(This article belongs to the Special Issue Natural Anticancer Molecules and Their Therapeutic Potential)
  • Article
  • Open Access
13 Citations
5,771 Views
18 Pages

The MEK/ERK Module Is Reprogrammed in Remodeling Adult Cardiomyocytes

  • Thomas Kubin,
  • Ayse Cetinkaya,
  • Natalia Kubin,
  • Peter Bramlage and ,
  • Bedriye Sen-Hild,
  • Praveen Gajawada,
  • Hakan Akintürk,
  • Markus Schönburg,
  • Wolfgang Schaper and
  • Manfred Richter
  • + 7 authors+ 2 authors

1 September 2020

Fetal and hypertrophic remodeling are hallmarks of cardiac restructuring leading chronically to heart failure. Since the Ras/Raf/MEK/ERK cascade (MAPK) is involved in the development of heart failure, we hypothesized, first, that fetal remodeling is...

(This article belongs to the Special Issue MAPK-ERK Pathway)
  • Article
  • Open Access
42 Citations
5,715 Views
18 Pages

Overactivation of Akt Contributes to MEK Inhibitor Primary and Acquired Resistance in Colorectal Cancer Cells

  • Masanobu Tsubaki,
  • Tomoya Takeda,
  • Masaki Noguchi,
  • Minami Jinushi and ,
  • Shiori Seki,
  • Yuusuke Morii,
  • Kazunori Shimomura,
  • Motohiro Imano,
  • Takao Satou and
  • Shozo Nishida
  • + 5 authors+ 0 author

25 November 2019

RAS and BRAF-mutated colorectal cancers are associated with resistance to chemotherapy and poor prognosis, highlighting the need for new therapeutic strategies. Although these cancers sometimes respond to mitogen activated protein kinase kinase (MEK)...

  • Article
  • Open Access
21 Citations
5,996 Views
19 Pages

3 February 2022

The Mitogen-Activated Protein Kinase (MAPK) signaling pathway plays an important role in cancer cell proliferation and survival. MAPKs’ protein kinases MEK1/2 serve as important targets in drug designing against cancer. The natural compounds&rs...

(This article belongs to the Special Issue Computational Methods in the Design of Anticancer Drugs)
  • Article
  • Open Access
30 Citations
8,970 Views
35 Pages

Substituted 3-Benzylcoumarins as Allosteric MEK1 Inhibitors: Design, Synthesis and Biological Evaluation as Antiviral Agents

  • Chao Wang,
  • Hao Zhang,
  • Fengrong Xu,
  • Yan Niu and ,
  • Yun Wu,
  • Xin Wang,
  • Yihong Peng,
  • Jing Sun,
  • Lei Liang and
  • Ping Xu
  • + 5 authors+ 0 author

21 May 2013

In order to find novel antiviral agents, a series of allosteric MEK1 inhibitors were designed and synthesized. Based on docking results, multiple optimizations were made on the coumarin scaffold. Some of the derivatives showed excellent MEK1 binding...

(This article belongs to the Section Medicinal Chemistry)
  • Case Report
  • Open Access
3 Citations
3,743 Views
9 Pages

Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series

  • Julie Niogret,
  • Valentin Derangère,
  • Corentin Richard,
  • Lisa Nuttin and ,
  • François Ghiringhelli,
  • Laure Favier,
  • Leila Bengrine Lefevre,
  • Anthony Bergeron,
  • Laurent Arnould and
  • Romain Boidot
  • + 5 authors+ 0 author

Low-grade serous carcinoma represents a minority of serous carcinoma. Although they have better prognosis than high-grade serous carcinoma, they respond poorly to chemotherapy. Thus, it appears necessary to find other treatments such as targeted ther...

(This article belongs to the Special Issue Molecular Pathophysiology of Uterine and Ovarian Diseases and Dysfunction 2.0)
  • Article
  • Open Access
1 Citations
2,368 Views
23 Pages

MYC Overexpression Enhances Sensitivity to MEK Inhibition in Head and Neck Squamous Cell Carcinoma

  • Cuicui Yang,
  • Xiaowu Pang,
  • Shaolei Teng,
  • Shamel Wilson and ,
  • Xinbin Gu and
  • Guiqin Xie
  • + 1 author+ 0 author

MEK inhibitors, such as trametinib, have shown therapeutic potential in head and neck squamous cell carcinoma (HNSCC). However, the factors influencing cancer cell sensitivity and resistance to MEK inhibition remain poorly understood. In our study, w...

(This article belongs to the Special Issue New Wave of Cancer Therapeutics: Challenges and Opportunities)
  • Review
  • Open Access
82 Citations
24,562 Views
12 Pages

Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway

  • Pui-Kei Wu,
  • Andrew Becker and
  • Jong-In Park

In response to extracellular stimuli, the Raf/MEK/extracellular signal-regulated kinase (ERK) pathway regulates diverse cellular processes. While mainly known as a mitogenic signaling pathway, the Raf/MEK/ERK pathway can mediate not only cell prolife...

(This article belongs to the Special Issue MAPK-ERK Pathway)
  • Review
  • Open Access
33 Citations
7,202 Views
18 Pages

BRAF and MEK Targeted Therapies in Pediatric Central Nervous System Tumors

  • Dario Talloa,
  • Silvia Triarico,
  • Pierpaolo Agresti,
  • Stefano Mastrangelo and ,
  • Giorgio Attinà,
  • Alberto Romano,
  • Palma Maurizi and
  • Antonio Ruggiero
  • + 3 authors+ 0 author

31 August 2022

BRAF is a component of the MAPK and PI3K/AKT/mTOR pathways that play a crucial role in cellular proliferation, differentiation, migration, and angiogenesis. Pediatric central nervous system tumors very often show mutations of the MAPK pathway, as dem...

(This article belongs to the Special Issue Childhood Brain Cancer Treatment)
  • Feature Paper
  • Review
  • Open Access
133 Citations
12,161 Views
18 Pages

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors

  • Karisa C. Schreck,
  • Stuart A. Grossman and
  • Christine A. Pratilas

28 August 2019

BRAF mutations have been identified as targetable, oncogenic mutations in many cancers. Given the paucity of treatments for primary brain tumors and the poor prognosis associated with high-grade gliomas, BRAF mutations in glioma are of considerable i...

(This article belongs to the Special Issue Oncogenic Forms of BRAF as Cancer Driver Genes)
  • Article
  • Open Access
10 Citations
6,633 Views
31 Pages

Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition

  • Antonella Catalano,
  • Mojca Adlesic,
  • Thorsten Kaltenbacher,
  • Rhena F. U. Klar and ,
  • Joachim Albers,
  • Philipp Seidel,
  • Laura P. Brandt,
  • Tomas Hejhal,
  • Philipp Busenhart and
  • Ian J. Frew
  • + 12 authors+ 7 authors

13 April 2021

Oncogenic mutations in RAS family genes arise frequently in metastatic human cancers. Here we developed new mouse and cellular models of oncogenic HrasG12V-driven undifferentiated pleomorphic sarcoma metastasis and of KrasG12D-driven pancreatic ducta...

(This article belongs to the Collection Drug Resistance and Novel Therapies in Cancers)
  • Article
  • Open Access
4 Citations
2,912 Views
17 Pages

Trametinib, a MEK1/2 Inhibitor, Protects Mice from Cisplatin- and Noise-Induced Hearing Loss

  • Richard D. Lutze,
  • Matthew A. Ingersoll,
  • Regina G. Kelmann and
  • Tal Teitz

Hearing loss is one of the most common types of disability; however, there is only one FDA-approved drug to prevent any type of hearing loss. Treatment with the highly effective chemotherapy agent, cisplatin, and exposure to high-decibel noises are t...

(This article belongs to the Section Medicinal Chemistry)
  • Article
  • Open Access
10 Citations
4,073 Views
22 Pages

Prognostic Gene Signature for Squamous Cell Carcinoma with a Higher Risk for Treatment Failure and Accelerated MEK-ERK Pathway Activity

  • Bohai Feng,
  • Kai Wang,
  • Esther Herpel,
  • Michaela Plath and ,
  • Wilko Weichert,
  • Kolja Freier,
  • Karim Zaoui and
  • Jochen Hess
  • + 3 authors+ 0 author

15 October 2021

Squamous cell carcinoma (SCC) is the most prevalent histological type of human cancer, including head and neck squamous cell carcinoma (HNSCC). However, reliable prognostic gene signatures for SCC and underlying genetic and/or epigenetic principles a...

(This article belongs to the Special Issue Head and Neck Cancer – the Rationale behind Different Therapeutic Approaches)
  • Article
  • Open Access
755 Views
13 Pages

MEK1 as a Synthetic Lethal Target with Cabozantinib in Renal Cell Carcinoma: Insights from CRISPR/Cas9 Screening

  • Hirofumi Yoshino,
  • Ikumi Fukuda,
  • Hideki Enokida,
  • Naohiko Seki and
  • Yusuke Goto

12 July 2026

Background/Objectives: Cabozantinib is a tyrosine kinase inhibitor that primarily targets MET. It has become an important drug in the treatment of renal cell carcinoma (RCC); however, many patients do not respond to cabozantinib treatment and there i...

(This article belongs to the Section Molecular Genetics and Genomics)
  • Article
  • Open Access
12 Citations
4,951 Views
20 Pages

A RAS-Independent Biomarker Panel to Reliably Predict Response to MEK Inhibition in Colorectal Cancer

  • Ulrike Pfohl,
  • Jürgen Loskutov,
  • Sanum Bashir,
  • Ralf Kühn and ,
  • Patrick Herter,
  • Markus Templin,
  • Soulafa Mamlouk,
  • Sergei Belanov,
  • Michael Linnebacher and
  • Christian R. A. Regenbrecht
  • + 9 authors+ 4 authors

1 July 2022

Background: In colorectal cancer (CRC), mutations of genes associated with the TGF-β/BMP signaling pathway, particularly affecting SMAD4, are known to correlate with decreased overall survival and it is assumed that this signaling axis plays a k...

(This article belongs to the Section Cancer Therapy)
  • Review
  • Open Access
7 Citations
5,876 Views
14 Pages

Neurofibromatosis Type 1 and MEK Inhibition: A Comprehensive Review with Focus on Selumetinib Therapy

  • George Imataka,
  • Shigeko Kuwashima,
  • Shujiro Hayashi,
  • Kei Ogino and ,
  • Eisei Hoshiyama,
  • Katsuhiko Naruse and
  • Hideaki Shiraishi
  • + 2 authors+ 0 author

17 July 2025

Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by a wide range of clinical manifestations, including café-au-lait macules, cutaneous neurofibromas, and an increased risk of certain malignancies. Historically, there has been...

(This article belongs to the Section Oncology)
  • Article
  • Open Access
34 Citations
5,285 Views
10 Pages

Polymorphisms in RAS/RAF/MEK/ERK Pathway Are Associated with Gastric Cancer

  • Patricio Gonzalez-Hormazabal,
  • Maher Musleh,
  • Marco Bustamante,
  • Juan Stambuk and ,
  • Raul Pisano,
  • Hector Valladares,
  • Enrique Lanzarini,
  • Hector Chiong,
  • Jorge Rojas and
  • Zoltan Berger
  • + 8 authors+ 3 authors

28 December 2018

The RAS/RAF/MEK/ERK pathway regulates certain cellular functions, including cell proliferation, differentiation, survival, and apoptosis. Dysregulation of this pathway leads to the occurrence and progression of cancers mainly by somatic mutations. Th...

(This article belongs to the Special Issue Genetic Epidemiology of Complex Diseases in Latin America)
  • Article
  • Open Access
5 Citations
2,671 Views
14 Pages

Class Effect Unveiled: PPARγ Agonists and MEK Inhibitors in Cancer Cell Differentiation

  • Rakefet Ben-Yishay,
  • Opher Globus,
  • Nora Balint-Lahat,
  • Sheli Arbili-Yarhi and ,
  • Neta Bar-Hai,
  • Vered Bar,
  • Sara Aharon,
  • Anna Kosenko,
  • Adi Zundelevich and
  • Dana Ishay-Ronen
  • + 6 authors+ 1 author

9 September 2024

Epithelial-to-mesenchymal transition (EMT) plays a major role in breast cancer progression and the development of drug resistance. We have previously demonstrated a trans-differentiation therapeutic approach targeting invasive dedifferentiated cancer...

(This article belongs to the Special Issue The Role of PPARs in Disease - Volume III)
  • Article
  • Open Access
14 Citations
3,962 Views
14 Pages

5 February 2020

Transforming growth factor β (TGFβ) is a pluripotent cytokine and regulates a myriad of biological processes. It has been established that TGFβ potently inhibits skeletal muscle differentiation; however, the molecular mechanism is not...

(This article belongs to the Special Issue Signalling Pathways in Skeletal Muscle Differentiation, Histogenesis and Repair)
  • Opinion
  • Open Access
41 Citations
7,985 Views
15 Pages

Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives

  • Christos Adamopoulos,
  • Donatella Delle Cave and
  • Athanasios G. Papavassiliou

28 January 2024

Pancreatic cancer represents a formidable challenge in oncology, primarily due to its aggressive nature and limited therapeutic options. The prognosis of patients with pancreatic ductal adenocarcinoma (PDAC), the main form of pancreatic cancer, remai...

(This article belongs to the Special Issue Molecular Mechanisms and Therapies of Pancreatic Cancer)
  • Article
  • Open Access
37 Citations
6,721 Views
25 Pages

10 March 2021

There is an unmet medical need for the development of new targeted therapeutic strategies for triple-negative breast cancer (TNBC). With drug combination screenings, we found that the triple combination of the protein kinase inhibitors (PKIs) of the...

(This article belongs to the Section Cancer Therapy)
  • Review
  • Open Access
492 Citations
34,485 Views
33 Pages

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

  • Ufuk Degirmenci,
  • Mei Wang and
  • Jiancheng Hu

13 January 2020

The RAS/RAF/MEK/ERK (MAPK) signaling cascade is essential for cell inter- and intra-cellular communication, which regulates fundamental cell functions such as growth, survival, and differentiation. The MAPK pathway also integrates signals from comple...

(This article belongs to the Special Issue GTPase Pathways in Health and Diseases)
  • Article
  • Open Access
1 Citations
569 Views
24 Pages

Unfolding Behavior and Conformational Changes Under Different Denaturing Conditions of MAPK 1 (MEK1)

  • Maria Gabriela Álvarez-Rodríguez,
  • Sonia Vega,
  • Felipe Hornos,
  • Adrian Velazquez-Campoy and ,
  • Bruno Rizzuti and
  • José L. Neira
  • + 1 author+ 0 author

Protein kinases have key roles in cells as they regulate diverse signal transduction pathways. Mitogen-activated protein kinase (MAPK) signaling route modulates several processes, such as cell proliferation, cell programming, metabolic changes and st...

(This article belongs to the Special Issue Feature Papers in Section "Biomacromolecules: Proteins, Nucleic Acids and Carbohydrates")
  • Article
  • Open Access
2 Citations
1,686 Views
16 Pages

Differential Sensitivity to MEK Inhibitors Highlights Distinct Entosis Mechanisms in BxPC3 and MCF7 Cells

  • Paweł Tyrna,
  • Julia Kostro,
  • Monika Olszanecka,
  • Piotr Szukało and
  • Izabela Młynarczuk-Biały

25 September 2025

Entosis is a form of cell-in-cell interaction observed in epithelial cancers, characterized by the internalization of one cell into another. This process is initiated by cell detachment, cadherin-mediated homotypic adhesion, and the formation of an e...

(This article belongs to the Topic Kinases in Cancer and Other Diseases, 2nd Edition)
  • Article
  • Open Access
7 Citations
7,629 Views
13 Pages

Activity-Based Proteomics Reveals Heterogeneous Kinome and ATP-Binding Proteome Responses to MEK Inhibition in KRAS Mutant Lung Cancer

  • Jae-Young Kim,
  • Paul A. Stewart,
  • Adam L. Borne,
  • Bin Fang and ,
  • Eric A. Welsh,
  • Yian Ann Chen,
  • Steven A. Eschrich,
  • John M. Koomen and
  • Eric B. Haura
  • + 4 authors+ 0 author

One way cancer cells can escape from targeted agents is through their ability to evade drug effects by rapidly rewiring signaling networks. Many protein classes, such as kinases and metabolic enzymes, are regulated by ATP binding and hydrolysis. We h...

of 24